Gilteritinib is a potent, ATP-competitive FLT3/AXL/ALK inhibitor. It blocks AKT/ERK/STAT5 signaling by binding to the active kinase conformation, effectively inhibiting proliferation and inducing apoptosis in mutated AML and ALK-rearranged cancers.
ASP2215 (Gilteritinib) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for ASP2215 (Gilteritinib) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.